Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Karyopharm Therapeutics Is Skyrocketing

By Brian Feroldi - Jul 3, 2019 at 4:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer after the company reports a regulatory win.

What happened

Shares of Karyopharm Therapeutics ( KPTI -0.73% ), a clinical-stage biopharmaceutical business focused on oncology, spiked 36% on as of 3:35 p.m. EDT on Wednesday, on heavy trading volume. The enthusiasm can be traced to the approval by the Food and Drug Administration of its lead product candidate.

So what

Karyopharm announced that the FDA has officially given the thumbs-up to selinexor -- now known as Xpovio -- as a treatment for the blood cancer multiple myeloma. Xpovio is the first and only nuclear export inhibitor that has won regulatory approval.

Xpovio is approved to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and who meet a few other criteria. The drug must also be used in combination with dexamethasone.

Doctor giving the thumbs-up sign

Traders are cheering the regulatory thumbs-up. Image source: Getty Images.

Now what

The FDA's decision to approve selinexor will likely come as a shock to many investors who've been following this company closely. In February an independent advisory panel voted 8 to 5 in favor of pausing selinexor's review until the results from an ongoing phase 3 study become available in the back half of this year. The agency even announced that it was going to delay its target decision date for the drug from April 6 to July 6, which usually isn't a good sign.

None of that matters now that the FDA has officially given the drug the go-ahead. Bulls who've held throughout the roller-coaster ride certainly deserve to cheer and take a victory lap today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Karyopharm Therapeutics Inc. Stock Quote
Karyopharm Therapeutics Inc.
$6.80 (-0.73%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.